B-type natriuretic peptide

B-type natriuretic peptide and cirrhosis progression

L. Y. Shi, Jin, R., Lin, C. J., Wu, J. S., Chen, X. W., Yu, Z., and Zhang, P. C., B-type natriuretic peptide and cirrhosis progression, vol. 14, pp. 5188-5196, 2015.

Brain natriuretic peptide (BNP) is used as a marker of cardiac dysfunction to predict heart failure mortality. The significance of the prognostic ability of BNP for liver cirrhosis remains unknown, although the levels of BNP seen in cirrhosis are high. We aimed to determine whether the BNP level is related to the stage of cirrhosis and could serve as a prognostic marker of cirrhosis (predict the 1-year all-cause mortality). We recruited 92 patients at different stages of cirrhosis and 81 controls matched by age and gender for this study.

Association of plasma B-type natriuretic peptide concentration with myocardial infarct size in patients with acute myocardial infarction

J. M. Niu, Ma, Z. L., Xie, C., and Zhang, Z. Q., Association of plasma B-type natriuretic peptide concentration with myocardial infarct size in patients with acute myocardial infarction, vol. 13, pp. 6177-6183, 2014.

B-type natriuretic peptide (BNP) is widely used in the treatment of early-stage heart failure and coronary heart disease. In this study, the association of plasma BNP concentration with myocardial infarct (MI) size in patients with acute myocardial infarction (AMI) was investigated. Eighty patients with AMI were enrolled in the MI group and 30 healthy volunteers were selected as the control group.

Subscribe to B-type natriuretic peptide